Our Scientific Advisors

Prof. Matthew Walker

Consultant Neurologist, Professor of Neurology (UCL) and Scientific Founder

Prof. Stephanie Schorge

Professor of Neuroscience (UCL) and Scientific Founder

Prof. Gabriele Lignani

Professor of Translational Neuroscience (UCL) and Scientific Founder

News

Prof. Matthew Walker

Consultant Neurologist, Professor of Neurology (UCL) and Scientific Founder

Matthew is Professor of Neurology at UCL in the Department of Clinical and Experimental Epilepsy and a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. He is also an expert in epilepsy and neurological sleep disorders. He has published several hundreds of articles on the diagnosis and treatment of epilepsy and novel treatment strategies for drug-resistant epilepsy and prolonged seizures (status epilepticus). He is a member of the Executive Committee of the ILAE (International League Against Epilepsy) and serves as the Chair of ILAE - Europe. In 2013, he received the Ambassador for Epilepsy award from the ILAE. Prof. Walker has MA BChir from Cambridge University and a PhD from University College London.

Prof. Stephanie Schorge

Professor of Neuroscience (UCL) and Scientific Founder

Stephanie is the Sophia Jex-Blake Professor of Neuroscience at UCL and the Head of the Research Department of Neuroscience, Physiology and Pharmacology (NPP). Prof. Schorge has a long-standing interest in how mutations in ion channels cause neurological diseases, and conversely how manipulating ion channels can be used to treat disease. Recently her work has focused on developing a portfolio of gene therapy approaches to treat severe drug-refractory epilepsy.

Prof. Gabriele Lignani

Professor of Translational Neuroscience (UCL) and Scientific Founder

Gabriele is Professor of Translational Neuroscience at the UCL Institute of Neurology. The focus of Prof. Lignani’s research lab is on finding novel gene therapy approaches for intractable neurological diseases with rapid potential for translation. He has pioneered the application of cutting-edge technologies such as CRISPR and synthetic promoters as therapeutics strategies for untreatable genetic diseases including Dravet Syndrome and refractory epilepsies. Prof. Lignani is on the editorial boards of Epilepsy Currents and Frontiers in Gene Editing. He was recently awarded the Michael Prize 2023 for the best scientific contribution to progress in the field of experimental epilepsy, and the ILAE European Epilepsy Young Investigator Award 2024, and was elected Fellow of the Royal Society of Biology.